<DOC>
	<DOCNO>NCT02085694</DOCNO>
	<brief_summary>A pilot study efficacy Lactobacillus CD2 lozenges prevent oral mucositis ( OM ) high-dose chemotherapy autologous hematopoietic stem cell transplantation . To test whether probiotic Lactobacillus brevis CD2 lozenges reduce incidence severity high-dose chemotherapy condition regimen induce OM patient undergo HSCT . Clinical activity define reduction incidence chemotherapy induce OM patient undergo HSCT .</brief_summary>
	<brief_title>Lactobacillus Brevis CD2 Preventing Oral Mucositis</brief_title>
	<detailed_description />
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Age 18 65 year Karnofsky Performance Score â‰¥ 70 % . Confirmed histological diagnosis multiple myeloma HSCT approve modality therapy Patients eligible receive highdose chemotherapy part condition regimen Concomitant co morbid condition present , control ongoing treatment ( e.g . hypertension , diabetes ) Serum creatinine &lt; 1.8mg/dl Total bilirubin &lt; 2mg/dl Liver enzyme within three time normal limit Expected survival &gt; 6 month . Pregnant woman lactate mother Patients history HIV infection Patients take investigational product last 4 week Patients untreated symptomatic dental infection Patients WHO Grade 3 4 oral Mucositis Other serious concurrent illness Inconclusive hematological diagnosis Patients sign symptom systemic infection Patient's/guardian 's refusal sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>